|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
POTENTIAL FOR INCREASED MYELOTOXICITY AND NEPHROTOXICITY
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
DECREASES THE HALF-LIFE OF DOXYCYCLINE
|
DECREASES THE HALF-LIFE OF DOXYCYCLINE
|
DECREASES THE HALF-LIFE OF DOXYCYCLINE
|
DECREASES THE HALF-LIFE OF DOXYCYCLINE
|
DECREASES THE HALF-LIFE OF DOXYCYCLINE
|
DECREASES THE HALF-LIFE OF DOXYCYCLINE
|
DEPRESSED PLASMA PROTHROMBIN ACTIVITY ; MAY REQUIRE DOWNWARD ADJUSTMENT OF THE ANTICOAGULANT DOSAGE
|
DEPRESSED PLASMA PROTHROMBIN ACTIVITY ; MAY REQUIRE DOWNWARD ADJUSTMENT OF THE ANTICOAGULANT DOSAGE
|
DEPRESSED PLASMA PROTHROMBIN ACTIVITY ; MAY REQUIRE DOWNWARD ADJUSTMENT OF THE ANTICOAGULANT DOSAGE
|
DEPRESSED PLASMA PROTHROMBIN ACTIVITY ; MAY REQUIRE DOWNWARD ADJUSTMENT OF THE ANTICOAGULANT DOSAGE
|
DEPRESSED PLASMA PROTHROMBIN ACTIVITY ; MAY REQUIRE DOWNWARD ADJUSTMENT OF THE ANTICOAGULANT DOSAGE
|
DEPRESSED PLASMA PROTHROMBIN ACTIVITY ; MAY REQUIRE DOWNWARD ADJUSTMENT OF THE ANTICOAGULANT DOSAGE
|
DEPRESSED PLASMA PROTHROMBIN ACTIVITY ; MAY REQUIRE DOWNWARD ADJUSTMENT OF THE ANTICOAGULANT DOSAGE
|
TETRACYCLINES CONCOMITANT USE MAY CAUSE BENIGN INTRACRANIAL HYPERTENSION
|
FOLIC ACID DEFICIENCY MAY PRECIPITATE WITH CONCURRENT USE
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CO-ADMINISTRATION WITH TETRACYCLINES MAY INCREASE DIGOXIN ABSORPTION IN PATIENTS WITH INACTIVATE DIGOXIN BY BACTERIAL METABOLISM IN THE LOWER INTESTINE, SO THAT DIGITALIS INTOXICATION MAY RESULT
|
CO-ADMINISTRATION WITH TETRACYCLINES MAY INCREASE DIGOXIN ABSORPTION IN PATIENTS WITH INACTIVATE DIGOXIN BY BACTERIAL METABOLISM IN THE LOWER INTESTINE, SO THAT DIGITALIS INTOXICATION MAY RESULT
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH IRON-CONTAINING PREPARATIONS MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
POTENTIAL FOR FATAL RENAL TOXICITY
|
CO-ADMINISTRATION WITH BARBITURATES DECREASES THE HALF-LIFE OF DOXYCYCLINE
|
CO-ADMINISTRATION WITH BARBITURATES DECREASES THE HALF-LIFE OF DOXYCYCLINE
|
CO-ADMINISTRATION WITH BARBITURATES DECREASES THE HALF-LIFE OF DOXYCYCLINE
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
MOLYBDENUM IMPAIRES THE ABSORPTION OF THE DRUG
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
CO-ADMINISTRATION WITH ANTACIDS CONTAINING ALUMINUM, MAGNESIUM, AND CALCIUM MAY IMPAIR ORAL ABSORPTION OF TETRACYCLINES
|
ALCOHOL ACCELERATE THE METABOLISM OF THE DRUG BY LIVER BY INDUCING HEPATIC ENZYMES
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
CALCIUM SALTS INTERFERE WITH ITS ABSORPTION FROM THE GUT
|
CALCIUM SALTS INTERFERE WITH ITS ABSORPTION FROM THE GUT
|